Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label, Multiple Dose Study of CHO-H01 Administered Intravenously as a Single Agent to Subjects With Refractory or Relapsed Follicular Lymphoma

NCT03221348 is registered in ClinicalTrials.gov with Cho Pharma Inc. as lead sponsor.

NCT NCT03221348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03221348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label, Multiple Dose Study of CHO-H01 Administered Intravenously as a Single Agent to Subjects With Refractory or Relapsed Follicular Lymphoma
Lead sponsor
Cho Pharma Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
March 31, 2018
Completion date
November 30, 2019
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma